Peter Scheu - LumiraDx Pres Operations
| LMDXDelisted Stock | USD 0.42 0.02 4.55% |
Insider
Peter Scheu is Pres Operations of LumiraDx
| Age | 59 |
| Phone | 44 11 7284 2535 |
| Web | https://www.lumiradx.com |
LumiraDx Management Efficiency
The company has return on total asset (ROA) of (0.2804) % which means that it has lost $0.2804 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.6448) %, meaning that it created substantial loss on money invested by shareholders. LumiraDx's management efficiency ratios could be used to measure how well LumiraDx manages its routine affairs as well as how well it operates its assets and liabilities.LumiraDx currently holds 401.25 M in liabilities. LumiraDx has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about LumiraDx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Petras | Sotera Health Co | 55 | |
| Ryan Douglas | Exagen Inc | N/A | |
| Werner Baumgartner | Psychemedics | N/A | |
| Alexander Dimitrief | Sotera Health Co | 65 | |
| Rebecca Fischer | Enzo Biochem | 52 | |
| Paul Beresford | Biodesix | N/A | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| Bobbi Coffin | Biodesix | N/A | |
| Jeffrey Bojar | Biodesix | N/A | |
| Gary Pestano | Biodesix | 57 | |
| Steven Graves | Sera Prognostics | N/A | |
| MBA MBA | Sera Prognostics | 70 | |
| Kristin Gibbs | Sotera Health Co | N/A | |
| Annette Baumgartner | Psychemedics | N/A | |
| Ryan Siurek | Biodesix | 52 | |
| Robert Hauzie | Sotera Health Co | N/A | |
| Sally Turner | Sotera Health Co | N/A | |
| Paul Kearney | Sera Prognostics | 56 | |
| Zvi David | DarioHealth Corp | 63 | |
| Michael MD | Sera Prognostics | N/A | |
| Robert Cawthorn | Biodesix | 87 | |
Management Performance
| Return On Equity | -15.64 | |||
| Return On Asset | -0.28 |
LumiraDx Leadership Team
Elected by the shareholders, the LumiraDx's board of directors comprises two types of representatives: LumiraDx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LumiraDx. The board's role is to monitor LumiraDx's management team and ensure that shareholders' interests are well served. LumiraDx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LumiraDx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Colleen McMillen, VP Communications | ||
| Jerome McAleer, Chief CoFounder | ||
| David DMS, Chief Officer | ||
| Dorian CPA, CFO Operations | ||
| Nigel Lindner, Chief Officer | ||
| David Scott, CTO CoFounder | ||
| Peter Scheu, Pres Operations | ||
| Ron Zwanziger, Chairman CoFounder | ||
| Andy Ward, National UK | ||
| Veronique Ameye, Exec Counsel |
LumiraDx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LumiraDx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.64 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (2.67) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 440.16 M | |||
| Shares Outstanding | 161.02 M | |||
| Shares Owned By Insiders | 55.41 % | |||
| Shares Owned By Institutions | 25.26 % | |||
| Number Of Shares Shorted | 1.43 M | |||
| Price To Earning | 13.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |